



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in and envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
On: 05/13/2009
By: Crystal Susa Printed: Crystal Susa

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		
				Application Number	10/737,144	
Substitute for form 1449A/PTO				Filing Date	12/15/2003	
				First Named Inventor	Yum, et al.	
Sheet <u>1</u> Of <u>1</u>				Group Art Unit	1618	
				Examiner Name	FUBARA, Blessing M	
				Attorney Docket Number	DURE-050	
U.S. PATENT DOCUMENTS						
Examiner's Initials	Cite No.	U.S. Patent Document Number	Name of Patentee or Applicant		Date of Publication (MM-DD-YYYY)	
FOREIGN PATENT DOCUMENTS						
Examiner's Initials	Cite No.	Foreign Patent Document Number	Country	Name of Patentee or Applicant	Date of Publication (MM-DD-YYYY)	Translation (Y/N)
	158	2008/023261	WO	Mannion, et al.	02-28-2008	N
OTHER PRIOR ART						
Examiner's Initials	Cite No.	AUTHOR, title of article, title of item, date, pages, volume/issue numbers, publisher, city and/or country published				Translation (Y/N)
	159	Cellulose Acetate Butyrate. In: European pharmacopoeia. 4 edn. Strasbourg Cedex, France: Council of Europe; 2001; p. 853-4.				
	160	Gilderman L., et al. "Remoxy™: A New Opioid Drug With Effective Analgesia and Abuse-Resistance." American Pain Society Annual Meeting, San Antonio, TX, May 2006.				
	161	Johnston LD, O'Malley PM, Bachman JG, Schulenberg, JE. "Monitoring the future. National results on adolescent drug use: overview of key findings" (NIH Publication No. 05-5726). Bethesda, MD: National Institute on Drug Abuse 2004.				
	162	Katz NP, et al. "Prescription monitoring of medical and non-medical Schedule II opioid abuse in Massachusetts: 1996-2005." Conference paper presented at the 69th College on Problems of Drug Dependence (CPDD), Quebec, Canada, 2007.				
	163	Meyer RJ, Hussain AS. Awareness topic: mitigating the risk of ethanol induced dose dumping from oral sustained/controlled release dosage forms. In: FDA's Advisory Committee for Pharmaceutical Science Meeting, October 2005.				
	164	Trescot AM, et al. "Opioid Guidelines in the Management of Chronic Non-Cancer Pain." Pain Physician. 2006;9:1-40.				
Examiner Signature				Date Considered		

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "Information Disclosure Statement." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made of that the cited items are inclusive of all the relevant and material citations that may be available publicly. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the Information Disclosure Statement be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 50-1953.